Document is current
Any future updates will be listed below
-
Authors
Gabriel, Kathrin https://orcid.org/0009-0009-6756-0014
Kobold, Sebastian https://orcid.org/0000-0002-5612-4673
- License Information
-
More Information
Article History
Received: 18 June 2025
Revised: 27 June 2025
Accepted: 29 June 2025
First Online: 10 July 2025
Competing interests
: K.G. reports no conflicts of interest. S.K. has received honoraria from Miltenyi, Galapagos, Cymab, Novartis, Plectonic, TCR2 Inc., Bristol Myers Squibb, and GlaxoSmithKline, and is listed as an inventor on several immuno-oncology patents. S.K. has also received license fees from TCR2 Inc. and Carina Biotech, as well as research support from TCR2 Inc., Tabby Therapeutics, Catalym GmbH, Plectonic GmbH, and Arcus Bioscience for work not related to the present manuscript.
